Radioligand Shows Promise in Metastatic Hormone-Sensitive Prostate Cancer

a week ago 2

(MedPage Today) -- In metastatic hormone-sensitive prostate cancer (mHSPC), adding the radioligand 177Lu-PSMA-617 (Pluvicto) to androgen deprivation therapy (ADT) and chemotherapy more than doubled biochemical recurrence-free survival (BRFS), the...